DYRK1B-STAT3 通过损害线粒体生物能量学驱动心脏肥厚与心力衰竭
该研究利用 DYRK1B 转基因与敲除小鼠及主动脉弓缩窄模型,发现 DYRK1B 在衰竭人心肌和肥厚小鼠心脏中表达上调,其过表达导致心功能障碍,而敲除可减轻心脏肥厚与心衰。机制上 DYRK1B 与 STAT3 结合增加其磷酸化及核聚集,下调 PGC-1α 损害线粒体生物能量学,抑制 DYRK1B 或 STAT3 可恢复心脏功能。
要点
- DYRK1B 在衰竭人心肌和肥厚小鼠心脏中表达上调。
- 心肌特异性过表达 DYRK1B 导致心功能障碍和心肌纤维化。
- 抑制 DYRK1B 或 STAT3 可恢复线粒体生物能量学改善心脏功能。
核心结论
- DYRK1B 通过 STAT3/PGC-1α 轴损害线粒体生物能量学,驱动心脏肥厚与心力衰竭进展。
- 抑制 DYRK1B 或 STAT3 活性可恢复心脏性能,为心衰提供潜在治疗选择。
研究设计与样本
- 研究构建 DYRK1B 转基因和敲除小鼠,采用主动脉弓缩窄建立体内心脏肥厚模型。
- 通过 RNA 测序分析和线粒体功能分析阐明 DYRK1B 及其下游介质的作用。
主要发现
- DYRK1B 在衰竭人心肌和肥厚小鼠心脏中表达明显上调。
- 心肌特异性 DYRK1B 过表达导致心脏功能障碍,伴左心室射血分数和缩短分数下降及心肌纤维化增加。
- 敲除 DYRK1B 减轻主动脉弓缩窄诱导的心脏肥厚和心力衰竭。
- DYRK1B 与 STAT3 直接结合增加其磷酸化和核聚集,下调 PGC-1α,损害线粒体生物能量学。
- 使用特异性抑制剂抑制 DYRK1B 或 STAT3 活性可恢复心脏性能并 rejuvenating 线粒体生物能量学。
临床怎么用
- DYRK1B-STAT3-PGC-1α 轴可作为心力衰竭的潜在治疗靶点。
- 抑制 DYRK1B 或 STAT3 活性可能改善线粒体生物能量学并恢复心脏功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure is a global public health issue that is associated with increasing morbidity and mortality. Previous studies have suggested that mitochondrial dysfunction plays critical roles in the progression of heart failure; however, the underlying mechanisms remain unclear. Because kinases have been reported to modulate mitochondrial function, we investigated the effects of DYRK1B (dual-specificity tyrosine-regulated kinase 1B) on mitochondrial bioenergetics, cardiac hypertrophy, and heart failure. METHODS: We engineered DYRK1B transgenic and knockout mice and used transverse aortic constriction to produce an in vivo model of cardiac hypertrophy. The effects of DYRK1B and its downstream mediators were subsequently elucidated using RNA-sequencing analysis and mitochondrial functional analysis. RESULTS: We found that DYRK1B expression was clearly upregulated in failing human myocardium and in hypertrophic murine hearts, as well. Cardiac-specific DYRK1B overexpression resulted in cardiac dysfunction accompanied by a decline in the left ventricular ejection fraction, fraction shortening, and increased cardiac fibrosis. In striking contrast to DYRK1B overexpression, the deletion of DYRK1B mitigated transverse aortic constriction-induced cardiac hypertrophy and heart failure. Mechanistically, DYRK1B was positively associated with impaired mitochondrial bioenergetics by directly binding with STAT3 to increase its phosphorylation and nuclear accumulation, ultimately contributing toward the downregulation of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1α). Furthermore, the inhibition of DYRK1B or STAT3 activity using specific inhibitors was able to restore cardiac performance by rejuvenating mitochondrial bioenergetics. CONCLUSIONS: Taken together, the findings of this study provide new insights into the previously unrecognized role of DYRK1B in mitochondrial bioenergetics and the progression of cardiac hypertrophy and heart failure. Consequently, these findings may provide new therapeutic options for patients with heart failure.
引用
- Zhuang, Jia, Chen, et al. DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics. Circulation. 2022. PMID: 35235343. doi:10.1161/CIRCULATIONAHA.121.055727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。